IgG4-RD Awareness Day is an opportunity to create conversation about the rare disease and the needs of IgG4-RD patients and caregivers. IgG4-related disease, or IgG4-RD, occurs when the immune system attacks healthy organs, leading to inflammation and the formation of tumor-like masses that can affect the pancreas, liver, kidneys and other organs.
It is notoriously difficult to diagnose and manage because it can mimic other conditions and present with a wide range of symptoms. Dr. Leonard Calabrese, a board-certified immunologist, rheumatologist and IgG4-RD specialist, explained that IgG4-RD is “a complex disease that impacts multiple organ systems, so there’s a lot to consider when diagnosing,” further emphasizing the need for continued education around the disease.
Awareness Builds Momentum
Challenges remain when it comes to accessing specialized care. Geographic and financial barriers can still delay diagnosis and access to treatment. However, increased visibility and growing engagement are contributing to a more informed and responsive care system.
IgG4-RD Awareness Day reflects improving recognition of the disease within the medical and patient communities. The first IgG4-RD Awareness Day was announced in 2024, and the IgG4ward Foundation launched a website where the community can find specialists, updates on treatment and the latest in IgG4-RD news. Together, these developments highlight the importance of continued awareness, education and access to care.
Advancing Rare Care
As the community celebrates the third formal recognition of this rare disease, the IgG4-RD landscape continues to advance. From no formal diagnosis 25 years ago, to the first FDA-approved treatment in 2025, with more on the way. People living with IgG4-RD are now experiencing increased awareness, improved diagnosis and expanded treatment options, all which contribute to a more comprehensive and streamlined care journey. This is crucial for patients who have struggled to get answers for too long. With continued collaboration between patients, clinicians, advocates and policymakers, the horizon looks promising.
